Literature DB >> 8069700

Malonate produces striatal lesions by indirect NMDA receptor activation.

R Henshaw1, B G Jenkins, J B Schulz, R J Ferrante, N W Kowall, B R Rosen, M F Beal.   

Abstract

We previously showed that local striatal injections of malonate produce age-dependent excitotoxic lesions. In the present study volumetric analysis confirmed that malonate produces age-dependent striatal lesions. Pretreatment with the non-competitive and competitive NMDA receptor antagonists, MK-801 and LY274614, and with lamotrigine resulted in significant protection in 4-month-old animals. In vivo magnetic resonance imaging of lesion area showed a significant correlation of increasing lesion size and lactate production in rats ranging from 1 to 12 months of age. Histological evaluation showed NADPH-diaphorase neurons were spared. The results provide further evidence that a subtle impairment of energy metabolism may play a role in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8069700     DOI: 10.1016/0006-8993(94)91412-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

Review 1.  Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.

Authors:  Peter J Adhihetty; M Flint Beal
Journal:  Neuromolecular Med       Date:  2008-11-13       Impact factor: 3.843

Review 2.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

Review 3.  Mitochondrial dysfunction in neurodegeneration.

Authors:  J M Cooper; A H Schapira
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

Review 4.  The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases.

Authors:  J B Schulz; R T Matthews; T Klockgether; J Dichgans; M F Beal
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

5.  Methylmalonyl-CoA mutase induction by cerebral ischemia and neurotoxicity of the mitochondrial toxin methylmalonic acid.

Authors:  P Narasimhan; R Sklar; M Murrell; R A Swanson; F R Sharp
Journal:  J Neurosci       Date:  1996-11-15       Impact factor: 6.167

6.  N-methyl-D-aspartate receptors are involved in the quinolinic acid, but not in the malonate pro-oxidative activity in vitro.

Authors:  Robson Luiz Puntel; Cristina Wayne Nogueira; João Batista Teixeira Rocha
Journal:  Neurochem Res       Date:  2005-03       Impact factor: 3.996

Review 7.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

8.  Malonate induces cell death via mitochondrial potential collapse and delayed swelling through an ROS-dependent pathway.

Authors:  Francisco J Fernandez-Gomez; Maria F Galindo; Maria Gómez-Lázaro; Victor J Yuste; Joan X Comella; Norberto Aguirre; Joaquín Jordán
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

9.  Huntingtin-associated protein (HAP1): discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase.

Authors:  X J Li; A H Sharp; S H Li; T M Dawson; S H Snyder; C A Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease.

Authors:  Faye Begeti; Adrian Y K Tan; Gemma A Cummins; Lucy M Collins; Natalie Valle Guzman; Sarah L Mason; Roger A Barker
Journal:  J Neurol       Date:  2013-08-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.